New Drug Approvals Archive - July 2014

July 2014

Beleodaq (belinostat) Injection

Date of Approval: July 3, 2014
Company: Spectrum Pharmaceuticals, Inc.
Treatment for: Peripheral T-cell Lymphoma

Beleodaq (belinostat) is a histone deacetylase (HDAC) inhibitor for the treatment of peripheral T-cell lymphoma (PTCL).

Kerydin (tavaborole) Topical Solution

Date of Approval: July 7, 2014
Company: Anacor Pharmaceuticals
Treatment for: Onychomycosis -- Toenail

Kerydin (tavaborole) is an oxaborole antifungal indicated for the topical treatment of onychomycosis of the toenails.

Rasuvo (methotrexate) Injection - formerly MPI-2505

Date of Approval: July 11, 2014
Company: Medac Pharma, Inc.
Treatment for: Rheumatoid Arthritis, Juvenile Rheumatoid Arthritis, Psoriasis

Rasuvo (methotrexate) is a subcutaneous, ready-to-use autopen formulation of methotrexate for the treatment of rheumatoid arthritis (RA), poly-articular-course juvenile RA and psoriasis.

Ruconest (C1 esterase inhibitor (recombinant)) - formerly Rhucin

Date of Approval: July 16, 2014
Company: Pharming Group NV
Treatment for: Hereditary Angioedema

Ruconest is a C1 esterase inhibitor [recombinant] indicated for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema (HAE).

Zydelig (idelalisib) Tablets

Date of Approval: July 23, 2014
Company: Gilead Sciences, Inc.
Treatment for: non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Follicular Lymphoma

Zydelig (idelalisib) is a phosphoinositide 3-kinase (PI3K) delta inhibitor for the treatment of chronic lymphocytic leukemia, relapsed follicular B-cell non-Hodgkin lymphoma, and relapsed small lymphocytic lymphoma.

Targiniq ER (naloxone and oxycodone) Extended-Release Tablets

Date of Approval: July 23, 2014
Company: Purdue Pharma L.P.
Treatment for: Pain

Targiniq ER (naloxone and oxycodone) is an opioid antagonist and opioid analgesic combination in a long-acting abuse-deterrent formulation for the management of chronic severe pain.

Ryanodex (dantrolene) Injectable Suspension

Date of Approval: July 22, 2014
Company: Eagle Pharmaceuticals, Inc.
Treatment for: Malignant Hyperthermia

Ryanodex (dantrolene) is a skeletal muscle relaxant in a concentrated formulation for the treatment of malignant hyperthermia.

Flonase Allergy Relief (fluticasone propionate) Nasal Spray

Date of Approval: July 23, 2014
Company: GlaxoSmithKline plc
Treatment for: Allergic Rhinitis

Flonase Allergy Relief (fluticasone propionate) is a once-a-day, over-the-counter corticosteroid nasal spray indicated for the relief hay fever symptoms.

Acticlate (doxycycline hyclate) Tablets

Date of Approval: July 25, 2014
Company: Aqua Pharmaceuticals, LLC
Treatment for: Bacterial Infection, Acne

Acticlate (doxycycline hyclate) is a tetracycline-class antibacterial indicated for the treatment of a number of infections, including adjunctive therapy in severe acne.

Striverdi Respimat (olodaterol) Inhalation Spray

Date of Approval: July 31, 2014
Company: Boehringer Ingelheim Pharmaceuticals Inc.
Treatment for: Chronic Obstructive Pulmonary Disease

Striverdi Respimat (olodaterol) is a once-daily, long-acting beta-agonist (LABA) for the maintenance treatment of chronic obstructive pulmonary disease (COPD).